Companies partner on gallium-68 imaging

By staff writers

May 6, 2020 -- ARTMS Products and Telix Pharmaceuticals have signed a partnership covering the manufacturing of a radiopharmaceutical-based imaging agent based on the gallium-68 isotope.

Calling their technology molecularly targeted radiation (MTR), the firms agreed to use the Quantm gallium-68 production system from ARTMS in the manufacture of Telix's prostate cancer imaging agent TLX591-CDx for PET imaging.

ARTMS' cyclotron technology will be used to produce high-activity gallium-68, which will then be validated for use with Telix's production process for TLX591-CDx. ARTMS also will provide Telix with technical personnel to assist with solid-target irradiation of zinc-68, and it will utilize the company's intellectual property for high-activity processing of gallium-68.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking